WilmerHale represented the underwriters in the underwritten public offering of 17,142,857 shares of common stock by Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. In connection with the public offering, Amylyx granted the underwriters a 30-day option to purchase up to an additional 2,571,428 shares of common stock at the public offering price, less the underwriting discounts and commissions. Amylyx received approximately $60.0 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. The offering priced on January 10, 2025 and closed on January 13, 2025.

The WilmerHale team representing the underwriters included Lisa Firenze, Ryan Brewer and Michelle Sidle with assistance from Barish Ozdamar on intellectual property matters and Heidi Treiber on FINRA matters.